Avidity Biosciences, Inc.

We are proud to serve on the Global Task Force of Project Mercury, an open collaboration spearheaded by the FSHD Society. This initiative unites global stakeholders to overcome challenges in delivering effective #FSHD therapies to patients. Recently, Josie Godfrey, a patient advocate and consultant for Project Mercury, and Amanda Hill, Director of Clinical Research at the FSHD Society, hosted a webcast sharing updates from Project Mercury and plans to build a global cohort of 10,000 clinical-trial ready patients by 2025. With our recently reported positive initial data from the Phase 1/2 FORTITUDE™ trial in people living with facioscapulohumeral muscular dystrophy (FSHD), we are excited about the potential to advance FSHD treatment options and improve lives worldwide. Watch the webcast here https://lnkd.in/e7yzaXqw and learn more about the Phase 1/2 FORTITUDE™ trial at https://lnkd.in/dH-56XKM

In the June issue of Drug Development & Delivery, Avidity’s Distinguished Scientist and Strategic Leader, Art Levin, PhD, discusses how we are developing a new class of RNA therapeutics with the potential to precisely target and modify the underlying genetic drivers of diseases. At Avidity, we’re leveraging our proprietary AOC platform to advance our clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (#DM1), facioscapulohumeral muscular dystrophy (#FSHD), and Duchenne muscular dystrophy (#DMD). In the last year, we have shared exciting data from all three programs, further reinforcing the promise of our AOC platform to profoundly improve people's lives by revolutionizing the delivery of RNA therapeutics. Read the full article: https://lnkd.in/eq-MCCVf

Meet Xabier Rivera, our summer #IT intern. Xabier recently graduated with a degree in criminal justice from San Diego State University and is working to pursue a master’s degree in cybersecurity engineering in the fall at the University of San Diego. During a career fair at SDSU, Xabier was drawn to our mission to profoundly improve the lives of people with #rarediseases due to his personal experience in the community. His belief in the transformative impact of R&D for patients was strengthened by his mother's diagnosis with a rare birth disorder. We’re excited to welcome Xabier to our team this summer and look forward to having other talented students join our internship program, where they can apply their academic knowledge to real-world settings while demonstrating our #BeAVID values. Learn more about our work at Avidity at https://lnkd.in/dH-56XKM

Last month we wrapped up the 2024 MDF Regional Conference Series after partnering with Myotonic Dystrophy Foundation for six impactful one-day events which provided an opportunity to connect with local myotonic dystrophy communities, patients, caregivers and advocates nationwide. At Avidity, patient and caregiver perspectives drive our research and development efforts, inspiring us as we stay committed to our mission to improving the lives of people affected by serious diseases. With the initiation of the global pivotal HARBOR study, we remain steadfast in our commitment to making a meaningful difference in the lives of people living with #DM1. Thank you to the MDF for organizing this series, the participants, and all who helped make these events so successful. Learn more about our DM1 clinical program: https://lnkd.in/dH-56XKM

We are proud to support the #LGBTQIA+ community as pride celebrations kick off in San Diego this week. In recognition of this year’s theme, “Making History Now,” San Diego Pride will host a series of festivities from July 13-21 to encourage future generations to blaze their own trails and make their own history. Join us as we champion our local communities and beyond: https://sdpride.org/

Happy Independence Day to our friends, families, the rare disease community, and the Avidity team! #FourthofJuly

On Friday, June 28, Avidity’s Henry Nchienzia, Ph.D will present data from the Phase 1/2 EXPLORE44™ clinical trial in healthy volunteers during Parent Project Muscular Dystrophy’s 30th Annual Conference in Orlando. We are excited to support this event and look forward to engaging with families, physicians, researchers, and industry leaders as we celebrate the incredible progress we’ve made together in the #DMD community. Join us at #PPMD2024 #PPMD30 and meet the Avidity team during the resource fair: https://lnkd.in/exuJZnwq

Diversity is central to who we are at Avidity, and we're proud to foster a work environment where everyone is welcomed, accepted, and celebrated. As we recognize #PrideMonth this June, we are proud to show our support for the LGBTQ+ community and reaffirm our commitment to creating a culture of respect, equality, and inclusivity. This year’s theme “Making History Now” encourages future generations to blaze their own path and make their own history, with local festivities kicking off this July during the San Diego Pride Festival. Join us as we come together to celebrate diversity, embrace inclusion, and champion progress https://sdpride.org/

Today we join the global facioscapulohumeral muscular dystrophy (#FSHD) community in celebrating #WorldFSHDDay. FSHD is a rare, progressive, and variable hereditary muscle-weakening condition that affects approximately 16,000 to 38,000 people in the U.S. alone. This month, we had the privilege of engaging with members of the FSHD community at the FSHD Society's FSHD Connect Conference. Listening to their stories provided invaluable insights into the challenges presented by FSHD and deepened our understanding of its impact on their lives. As we continue to advance our Phase 1/2 FORTITUDE™ clinical trial, we are committed to supporting and empowering the patient community and bringing a much-needed treatment to people living with this #raredisease. See our press release: https://lnkd.in/eBWrjF_s

Join our CEO Sarah Boyce and CMO Steve Hughes on June 20 at 11:20 am ET for a #fireside chat during the Cowen RNA Summit to learn more about the exciting progress we are making with our three clinical programs for #DM1, #DMD44, and #FSHD. To view the webcast, visit: https://lnkd.in/grNtBgD